Guggenheim initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $6 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Buy Rating for Unicycive Therapeutics: Competitive Advantages of Oxylanthanum Carbonate in Hyperphosphatemia Treatment
- Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate
- Unicycive presents new patient-level data from Phase 2 study of OLC
- Buy Rating for Unicycive Therapeutics Amid Favorable Risk/Reward and Strategic Growth Opportunities
- Promising Prospects for Unicycive Therapeutics: Buy Rating Backed by Upcoming Milestones and Strategic Preparations
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue